Insight on mechanism of hyponatraemia induced by low-dose intravenous pulse cyclophosphamide

Se Jin Park; Ji Hong Kim; Jae Il Shin

doi:10.1093/ndt/gfq429

RDLNetworkEkosistem

Hakkımızda SSS

Giriş yap Başla

İnönü Üniversitesi Karşısı
Malatya Teknokent-B No:3/1 İç Kapı No: B26
Battalgazi/Malatya

+90 538 363 3074 info@rawdatalibrary.net

Hakkımızda SSS Gizlilik Şartlar İletişim

Insight on mechanism of hyponatraemia induced by low-dose intravenous pulse cyclophosphamide — Se Jin Park (2010) | RDL Network

Back

Home
Publications
Insight on mechanism of hyponatraemia induced by low-dose intravenous pulse cyclophosphamide

Shared by

Jae Il Shin

Insight on mechanism of hyponatraemia induced by low-dose intravenous pulse cyclophosphamide

Letter 2010 en

Authors

SP
Se Jin Park
JK
Ji Hong Kim
JS
Jae Il Shin

Related publications

Article2012

A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis

Efstathios Kastritis, Evangelos Terpos, Μαρία Ρούσσου, Maria Gavriatopoulou, Constantinos Pamboukas, Ioannis Boletis, Smaragda Marinaki, Theofanis Apostolou, Nikitas Nikitas, Georgios Gkortzolidis, Eurydiki Michalis, Sossana Delimpasi, Meletios A Dimopoulos

Discussion(0)

No comments yet. Be the first to comment.

Publication Info

DOI: 10.1093/ndt/gfq429
Year: 2010
Published: —
Language: en

Letter Details

Volume: 25
Issue: 10
Link Of The Paper: https://doi.org/10.1093/ndt/gfq429

Timeline

Created:June 19, 2026

Article2002

Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.

Ioannis Pakas, John P A Ioannidis, Katerina Malagari, Fotini N. Skopouli, Haralampos Μ. Moutsopoulos, Panayiotis G. Vlachoyiannopoulos

Article2008

Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model

Ana P. Castaño, Paweł Mróz, Mei X. Wu, Michael R Hamblin

Article2002

Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.

Shan Man, Guido Bocci, Giulio Francia, Shane K. Green, Serge Jothy, Douglas Hanahan, Peter Böhlen, Daniel J. Hicklin, Gabriele Bergers, Robert S. Kerbel

Article2018

Phase 2 study of all‐oral ixazomib, cyclophosphamide and low‐dose dexamethasone for relapsed/refractory multiple myeloma

Shaji Kumar, Norbert Grząśko, Sosana Delimpasi, W Wiktor-Jędrzejczak, Sebastian Grosicki, Marie‐Christine Kyrtsonis, Andrew Spencer, Neeraj Gupta, Zhaoyang Teng, Catriona Byrne, Richard Labotka, Meletios A Dimopoulos